Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gefitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00005806
What this trial is testing

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00071994
What this trial is testing

Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

Who this might be right for
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer+1 more
National Cancer Institute (NCI) 59
Testing effectiveness (Phase 2)Study completedNCT00588445
What this trial is testing

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Who this might be right for
Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
Memorial Sloan Kettering Cancer Center 65
Large-scale testing (Phase 3)UnknownNCT02338011
What this trial is testing

Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)

Who this might be right for
Non-Small Cell Lung CancerBrain MetastasesEGFR Gene Mutation
Shanghai Chest Hospital 210
Testing effectiveness (Phase 2)Study completedNCT00255463
What this trial is testing

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Who this might be right for
Breast Cancer
AstraZeneca 185
Large-scale testing (Phase 3)Study completedNCT00234429
What this trial is testing

Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

Who this might be right for
Colorectal Cancer
AstraZeneca 74
Testing effectiveness (Phase 2)Study completedNCT00130702
What this trial is testing

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Who this might be right for
Myelogenous Leukemia, Acute
Dana-Farber Cancer Institute 18
Early research (Phase 1)Ended earlyNCT03599518
What this trial is testing

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Daiichi Sankyo Co., Ltd. 20
Large-scale testing (Phase 3)UnknownNCT03203590
What this trial is testing

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Who this might be right for
2-year Disease-Free Survival
Sun Yat-sen University 590
Post-approval studies (Phase 4)Ended earlyNCT00536107
What this trial is testing

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 14
Testing effectiveness (Phase 2)Study completedNCT00229697
What this trial is testing

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Who this might be right for
Breast Neoplasms
AstraZeneca 317
Testing effectiveness (Phase 2)Study completedNCT00238797
What this trial is testing

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

Who this might be right for
Glioblastoma
AstraZeneca 36
Testing effectiveness (Phase 2)Study completedNCT01485809
What this trial is testing

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

Who this might be right for
Squamous Cell Carcinoma of Bronchus
Seoul Veterans Hospital 36
Testing effectiveness (Phase 2)Study completedNCT01783834
What this trial is testing

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Who this might be right for
Previous Treated Metastatic Non-small Cell Lung Cancer
Gachon University Gil Medical Center 95
Testing effectiveness (Phase 2)Study completedNCT01167244
What this trial is testing

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 11
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Not applicableUnknownNCT02282267
What this trial is testing

Blood Detection of EGFR Mutation For Iressa Treatment

Who this might be right for
Lung Adenocarcinoma
Peking University Cancer Hospital & Institute 188
Testing effectiveness (Phase 2)Study completedNCT02804776
What this trial is testing

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Who this might be right for
Non-small Cell Lung Cancer
National Cancer Centre, Singapore 15
Testing effectiveness (Phase 2)Study completedNCT00016991
What this trial is testing

ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse

Who this might be right for
Brain and Central Nervous System Tumors
Duke University
Testing effectiveness (Phase 2)WithdrawnNCT01928160
What this trial is testing

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Next Page